How to buy Nuvectis Pharma stock (Nuvectis Pharma)

Nuvectis Pharma is a biotechnology business based in the US. Nuvectis Pharma shares (NVCT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.22 – an increase of 15.49% over the previous week. Nuvectis Pharma employs 13 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Nuvectis Pharma stock

Buy Nuvectis Pharma stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Nuvectis Pharma stock price (NASDAQ: NVCT)

Use our graph to track the performance of NVCT stocks over time.

Nuvectis Pharma shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$5.22
52-week range	$4.44 - $12.10
50-day moving average more info button	$6.36
200-day moving average more info button	$6.74
Wall St. target price	$22.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.16

Is it a good time to buy Nuvectis Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nuvectis Pharma price performance over time

Historical closes compared with the close of $5.02 from 2024-12-26

1 week (2024-12-20)	11.06%
1 month (2024-11-27)	-4.92%
3 months (2024-09-27)	-18.77%
6 months (2024-06-28)	-20.70%

1 year (2023-12-28)	-41.42%
2 years (2022-12-28)	-32.30%
3 years (2021-12-24)	N/A
5 years (2019-12-24)	N/A

Nuvectis Pharma financials

Gross profit TTM	$0
Return on assets TTM	-60.86%
Return on equity TTM	-140%
Profit margin	0%
Book value	$0.58
Market Capitalization more info button	$89.8 million

TTM: trailing 12 months

Nuvectis Pharma share dividends

We're not expecting Nuvectis Pharma to pay a dividend over the next 12 months.

You may also wish to consider:

• Merck-and-Company (MRK.US) (3.3% forward annual dividend yield)
• Pfizer (PFE.US) (6.53% forward annual dividend yield)
• Novartis AG ADR (NVS.US) (3.85% forward annual dividend yield)

Nuvectis Pharma share price volatility

Over the last 12 months, Nuvectis Pharma's shares have ranged in value from as little as $4.44 up to $12.1. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nuvectis Pharma's is 0.404. This would suggest that Nuvectis Pharma's shares are less volatile than average (for this exchange).

To put Nuvectis Pharma's beta into context you can compare it against those of similar companies.

• Merck-and-Company (MRK.US): 0.411
• Pfizer (PFE.US): 0.615
• Novartis AG ADR (NVS.US): 0.505

Nuvectis Pharma overview

Nuvectis Pharma, Inc. , a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc.

Frequently asked questions

What percentage of Nuvectis Pharma is owned by insiders or institutions?
Currently 51.776% of Nuvectis Pharma shares are held by insiders and 6.954% by institutions. How many people work for Nuvectis Pharma?
Latest data suggests 13 work at Nuvectis Pharma. When does the fiscal year end for Nuvectis Pharma?
Nuvectis Pharma's fiscal year ends in December. Where is Nuvectis Pharma based?
Nuvectis Pharma's address is: 1 Bridge Plaza, Fort Lee, NJ, United States, 07024 What is Nuvectis Pharma's ISIN number?
Nuvectis Pharma's international securities identification number is: US67080T1088